Khetan Riya, Dharmayanti Cintya, Gillam Todd A, Kübler Eric, Klingler-Hoffmann Manuela, Ricciardelli Carmela, Oehler Martin K, Blencowe Anton, Garg Sanjay, Albrecht Hugo
Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Applied Chemistry and Translational Biomaterials Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Cancers (Basel). 2022 May 10;14(10):2362. doi: 10.3390/cancers14102362.
The five-year survival rate for women with ovarian cancer is very poor despite radical cytoreductive surgery and chemotherapy. Although most patients initially respond to platinum-based chemotherapy, the majority experience recurrence and ultimately develop chemoresistance, resulting in fatal outcomes. The current administration of cytotoxic compounds is hampered by dose-limiting severe adverse effects. There is an unmet clinical need for targeted drug delivery systems that transport chemotherapeutics selectively to tumor cells while minimizing off-target toxicity. G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, and many are overexpressed in solid tumors, including ovarian cancer. This review summarizes the progress in engineered nanoparticle research for drug delivery for ovarian cancer and discusses the potential use of GPCRs as molecular entry points to deliver anti-cancer compounds into ovarian cancer cells. A newly emerging treatment paradigm could be the personalized design of nanomedicines on a case-by-case basis.
尽管进行了根治性细胞减灭术和化疗，卵巢癌女性的五年生存率仍然很低。虽然大多数患者最初对铂类化疗有反应，但大多数人会复发并最终产生化疗耐药性，导致致命后果。目前细胞毒性化合物的给药受到剂量限制的严重不良反应的阻碍。临床上迫切需要一种靶向给药系统，能够将化疗药物选择性地输送到肿瘤细胞，同时将脱靶毒性降至最低。G蛋白偶联受体（GPCRs）是最大的膜受体家族，许多在实体瘤中过度表达，包括卵巢癌。这篇综述总结了用于卵巢癌药物递送的工程纳米颗粒研究进展，并讨论了将GPCRs作为分子切入点将抗癌化合物递送至卵巢癌细胞的潜在用途。一种新出现的治疗模式可能是根据具体情况进行纳米药物的个性化设计。
